Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 + Docetaxel in Relapsed/Refractory NSCLC
NCT00544960Phase 2Completed
- Sponsor
- Ascenta Therapeutics
- Start
- Sep 2007
- Primary completion
- Nov 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in non-small cell lung cancer (NSCLC), sponsored by Ascenta Therapeutics. Started Sep 2007; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00544960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00544960.